Statin-treated patients in the third tertile presented a significantly lower rate of adverse events at 30 days ( 7.2 % vs. 17.4 % , p = 0.043 ) with a trend toward better outcome at 6 months ( 6.02 % vs. 13.04 % , p = 0.12 ) .